[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 106
6. Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B, German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL): Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer; 2006 Jan 1;106(1):136-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
  • BACKGROUND: Patients with aggressive lymphoma and high-risk features at the time of diagnosis are reported to have a poor prognosis with standard therapy.
  • In the current study, the authors increased the doses and dose intensity of drugs used for the conventional first-line therapy of aggressive lymphoma and designed a Phase II randomized trial that compared four and six courses of dose-escalated CHOP plus etoposide (megaCHOEP) supported by the transplantation of peripheral blood stem cells.
  • METHODS: Eighty-four patients age < 60 years with aggressive lymphoma and elevated lactate dehydrogenase (LDH) levels were randomized to receive either 4 (Arm A) or 6 (Arm B) courses of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (megaCHOEP).
  • These results also may explain the failure of HDT with low early dose intensity to improve the results obtained with conventional chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Antigens, CD34 / immunology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prospective Studies. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16331635.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


7. Tsunoda S, Kobayashi H, Inoue K, Izumi T, Akutsu M, Katano S, Ueda T, Shirai T, Masuda Y, Ohmine K, Nagashima T, Ueda M, Takagi S, Muroi K, Ozawa K, Kano Y: [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2007 Jun;34(6):885-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
  • We conducted a clinical study of MTX-HOPE (day 1, methotrexate 20 mg per os (po); day 2, hydrocortisone 100 mg intravenous (iv), vincristine 1 mg iv; day 3,4 sobuzoxane 400 mg po; etoposide 25 mg po, repeating every 2 or 3 weeks) in 14 relapsed or refractory patients with non-Hodgkin's lymphoma.
  • Grade 4 neutropenia and thrombocytopenia were observed in 4 and 2 patients,and grade 3 GPT-elevation and stomatitis in two and one, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / mortality. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Male. Methotrexate / administration & dosage. Middle Aged. Neutropenia / chemically induced. Piperazines / administration & dosage. Survival Rate. Thrombocytopenia / chemically induced. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565251.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Piperazines; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; R1308VH37P / sobuzoxane; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G: Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol; 2010 May 1;28(13):2233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patients developed transformation to high-grade non-Hodgkin's lymphoma nor myelodysplasia.
  • Low expression levels of human concentrative nucleoside transporter 1 (hCNT1) were correlated with the failure to achieve a CR (P = .024), whereas no association with Zap-70 expression was found.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cladribine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Genotype. Humans. Immunophenotyping. Injections, Subcutaneous. Italy. Kaplan-Meier Estimate. Male. Membrane Transport Proteins / genetics. Membrane Transport Proteins / metabolism. Middle Aged. Patient Selection. Phenotype. Prospective Studies. Rituximab. Time Factors. Treatment Outcome. ZAP-70 Protein-Tyrosine Kinase / genetics. ZAP-70 Protein-Tyrosine Kinase / metabolism


9. Paydas S, Ergin M, Erdogan S, Seydaoglu G: Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res; 2008 Sep;32(9):1424-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas.
  • BACKGROUND AND AIM: EBV is an important virus in the pathogenesis of NHL.
  • The viral latent protein LMP1, may play a role by inducing expression of angiogenic factors In this study EBV-LMP1 and VEGF-A expressions have been studied in cases with NHL and prognostic significance of these has been evaluated.
  • PATIENTS AND METHODS: One hundred seventy-seven cases (60 had low grade lymphoma (LGL), 117 had aggressive lymphoma (AL)) with NHL have been included in this analysis.
  • EBV positivity was associated with VEGF-A expression in diffuse large B cell lymphoma (DLBCL) (0.045).
  • Targeting both the angiogenesis and EBV may be important in the therapy of cases with NHL expressing EBV and/or VEGF-A.
  • [MeSH-major] Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Non-Hodgkin / metabolism. Vascular Endothelial Growth Factor A / metabolism. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282597.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Viral Matrix Proteins
  •  go-up   go-down


10. Fabre-Guillevin E, Tabrizi R, Coulon V, Monnereau A, Eghbali H, Soubeyran I, Soubeyran P: Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma; 2006 Apr;47(4):603-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.
  • The purpose of this study was to assess the prognostic value of a large panel of cytokines in aggressive non-Hodgkin's lymphoma (NHL) and to confront it to parameters of the International Prognostic Index (IPI).
  • In the intermediate group risk defined by IPI, patients presenting high level of sIL-2R or IL-6 demonstrated lower CR rate and survival than those with low level.
  • In conclusion, sIL-2R and IL-6 serum levels are elevated in high grade NHL and are correlated to CR, OS and FFS, but this study did not support their independent prognostic value.
  • However, sIL-2R and IL-6 measurements may improve risk assignment by IPI and allow a better prognostic evaluation of patients with intermediate prognosis NHL.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Interleukin-10 / biosynthesis. Interleukin-2 / biosynthesis. Interleukin-4 / biosynthesis. Interleukin-6 / biosynthesis. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / therapy. Receptors, Interleukin-2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Apr;47(4):570-2 [16886266.001]
  • (PMID = 16690518.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Interleukin-6; 0 / Receptors, Interleukin-2; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4
  •  go-up   go-down


11. Robak T, Szmigielska-Kapłon A, Błoński JZ, Kasznicki M, Chojnowski K: Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies. Chemotherapy; 2005 Aug;51(5):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We determined the effectiveness and toxicity of combined chemotherapy consisting of etoposide 100 mg/m(2)/day i.v. and cladribine (2-CdA) 0.12 mg/kg/day i.v. each for 5 days (EC regimen) in the treatment of refractory or relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cladribine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infection / chemically induced. Infusions, Intravenous. Male. Middle Aged. Neutropenia / chemically induced. Recurrence. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16088121.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 6PLQ3CP4P3 / Etoposide; EC regimen 2
  •  go-up   go-down


12. Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA: A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Dec 1;12(23):7046-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
  • PURPOSE: The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years.
  • Fifty percent to 75% of patients with low-grade or follicular NHL respond to rituximab therapy.
  • Therefore, a large, multicenter phase 2 trial to assess the effects of rIL-2 on rituximab therapy in patients with rituxumab-refractory low-grade NHL was conducted.
  • EXPERIMENTAL DESIGN: The combination of rituximab and rIL-2 was studied in 57 patients with rituximab-refractory low-grade NHL (i.e., patients must have received a single-agent course of rituximab and showed no tumor response, or had a response lasting <6 months). I.V. rituximab was given at 375 mg/m(2) (weeks 1-4). S.C. rIL-2 was given thrice a week at 14 MIU (weeks 2-5) and at 10 MIU (weeks 6-9).
  • RESULTS: Rituximab plus rIL-2 combination therapy was safe and generally well tolerated, but responses were low.
  • However, these findings do not directly translate into meaningful clinical benefit for patients with rituxumab-refractory NHL.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Interleukin-2 / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD / genetics. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Humans. Injections, Intravenous. Injections, Subcutaneous. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Polymorphism, Genetic / genetics. Receptors, IgG / genetics. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145827.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K01 CA95426-01A1; United States / NCI NIH HHS / CA / K08 CA93518-01; United States / NCI NIH HHS / CA / K23 CA102155
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / FCGR3A protein, human; 0 / Fc gamma receptor IIA; 0 / Interleukin-2; 0 / Receptors, IgG; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


13. Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL: Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med; 2007 Jan;48(1):150-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
  • Pulmonary involvement is common in patients with non-Hodgkin's lymphoma (NHL). (90)Y- and (131)I-anti-CD20 antibodies (ibritumomab tiuxetan and tositumomab, respectively) have been approved for the treatment of refractory low-grade follicular NHL.
  • In this work, we used Monte Carlo-based dosimetry to compare the potential of (90)Y and (131)I, based purely on their emission properties, in targeted therapy for NHL lung metastases of various nodule sizes and tumor burdens.
  • METHODS: Lung metastases were simulated as spheres, with radii ranging from 0.2 to 5.0 cm, which were randomly distributed in a voxelized adult male lung phantom.
  • CONCLUSION: Monte Carlo-based dosimetry was performed to compare the therapeutic potential of (90)Y and (131)I targeting of lung metastases in NHL patients. (131)I provided a therapeutic advantage over (90)Y, especially in tumors with radii less than 2.0 cm and at lower tumor burdens.
  • For both (90)Y- and (131)I-labeled antibodies, treatment is more efficacious when applied to metastatic NHL cases with lower tumor burdens. (131)I has advantages over (90)Y in treating smaller lung metastases.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2006 Dec;47(12):1985-94 [17138741.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2934-42 [11049969.001]
  • [Cites] J Nucl Med. 2001 Jun;42(6):967-74 [11390564.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3186-92 [11595713.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):165-72 [15023434.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1555-62 [10947258.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1259-66 [10942366.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7565-73 [16186600.001]
  • [Cites] Pediatr Radiol. 2004 Feb;34(2):120-4 [14605781.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):145-55 [14716739.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2351-7 [12750161.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):111-8 [12517786.001]
  • [Cites] J Nucl Med. 2002 Nov;43(11):1507-29 [12411555.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1316-23 [10715303.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):327-37 [14960657.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1023-7 [15937315.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S [15653661.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3270-8 [9779701.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2636-41 [9406718.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):477-85 [9247292.001]
  • [Cites] Phys Med Biol. 1996 Oct;41(10):1871-84 [8912367.001]
  • [Cites] Leuk Lymphoma. 1996 Jan;20(3-4):229-37 [8624461.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1219-24 [7692295.001]
  • [Cites] J Nucl Med. 1993 Mar;34(3):448-54 [8441037.001]
  • [Cites] J Nucl Med. 2004 Jul;45(7):1224-32 [15235070.001]
  • (PMID = 17204712.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116477-01A1; United States / NCI NIH HHS / CA / R01 CA116477; United States / NCI NIH HHS / CA / R01 CA116477-01A1; United States / NCI NIH HHS / CA / R01CA116477
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  • [Other-IDs] NLM/ NIHMS246413; NLM/ PMC2967041
  •  go-up   go-down


1
Advertisement
4. Zhang LB, Sun YE, Yu CH, Liu Y: [Clinical diagnosis and surgical treatment of primary pulmonary lymphoma]. Zhonghua Wai Ke Za Zhi; 2006 Jan 15;44(2):97-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical diagnosis and surgical treatment of primary pulmonary lymphoma].
  • OBJECTIVE: To study the clinical characteristics, the principles of diagnosis and surgical treatment for primary pulmonary lymphoma.
  • METHOD: Ten patients with primary pulmonary lymphoma were treated surgically and their clinical characteristics, the experiences of clinical diagnosis and surgical treatment were analyzed.
  • Only 2 cases were diagnosed as primary pulmonary lymphoma by percutaneous needle biopsy and pathologic examination.
  • All cases with non-Hodgkin's lymphoma received regular chemotherapy (MOPP and ABVD scheme for 1 case with Hodgkin's disease respectively, CHOP for 8 cases with non-Hodgkin's lymphoma), and 3 cases received radiotherapy postoperatively.
  • RESULTS: Eight cases were non-Hodgkin's lymphoma (B-type) and 2 cases were Hodgkin's disease (mixed type) confirmed by pathological examination.
  • Six cases with non-Hodgkin's lymphoma (3 cases for stage IE, 2 cases for stage II 1E, and 1 case for stage II 2E W) had been surviving for 18-42 months until the follow-up.
  • Two cases with non-Hodgkin's lymphoma (stage II 2E, B-cell, low-grade) and 2 cases with Hodgkin's disease (stage IE and II 2E, mixed type) died in 24, 32, 8 and 17 months postoperatively respectively.
  • CONCLUSIONS: Primary pulmonary lymphoma is a rare type of malignant lung neoplasm without special clinical features.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Lymphoma / diagnosis. Lymphoma / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Pneumonectomy / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620666.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, Bradley JA: Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation; 2006 Aug 15;82(3):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In view of the similarities between monomorphic PTLD and non-Hodgkin's lymphoma in the general population, our policy is to treat monomorphic PTLD with anthracycline-based chemotherapy as first-line treatment.
  • RESULTS: Of the 18 patients with PTLD, 13 had high-grade malignant lymphoma on diagnostic biopsy and received anthracycline-based chemotherapy and reduction in immunosuppression as first-line therapy.
  • Four (22%) patients had polymorphic PTLD on diagnostic biopsy (of which two were re-classified as monomorphic) and one had a low-grade malignant lymphoma.
  • CONCLUSION: The use of anthracycline-based chemotherapy and reduction of immunosuppression as first-line treatment in adults with monomorphic PTLD is well tolerated and achieves sustained complete remission in around 70% of patients with a low risk of graft loss.
  • [MeSH-major] Anthracyclines / therapeutic use. Kidney Transplantation. Lymphoma / drug therapy. Lymphoma / pathology. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906036.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


16. Wöhrer S, Raderer M, Kaufmann H, Hejna M, Chott A, Zielinski CC, Drach J: Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. Onkologie; 2005 Feb;28(2):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.
  • Since indolent non-Hodgkin's lymphomas (NHL) represent about 35% of all malignant lymphomas and mainly affect elderly patients, availability of a conventional chemotherapy regimen with high efficacy and low toxicity is of clinical importance.
  • PATIENTS AND METHODS: We retrospectively analysed 13 patients with advanced indolent NHL who were treated with 6-9 cycles of MCP: mitoxantrone 8 mg/m2 (days 1 and 2), chlorambucil 3 x 3 mg/m2 (days 1-5) and prednisone 25 mg (days 1-5) every 4 weeks.
  • The main toxicity (66%) was neutropenia (WHO grade III).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chlorambucil / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Retrospective Studies. Severity of Illness Index. Treatment Outcome

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662110.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 18D0SL7309 / Chlorambucil; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; MCP protocol
  •  go-up   go-down


17. Planinc-Peraica A, Kolonić SO, Radić-Kristo D, Dominis M, Jaksić B: Serum immunoglobulins in non-Hodgkin's lymphoma patients. Coll Antropol; 2010 Jun;34(2):407-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum immunoglobulins in non-Hodgkin's lymphoma patients.
  • Serum proteins and immunoglobulin (Ig) findings in 119 non-Hodgkin's lymphoma (NHL) patients were analysed.
  • Out of them 96 (81%) patients had B non-Hodgkin lymphoma (B-NHL), and 23 (19%) T-NHL.
  • Indolent type of NHL was more frequent (77 patients, 65%), then aggressive type of NHL (42 patients, 35%).
  • In contrast to albumin, low levels of other protein fractions (alpha1-, alpha2-, and beta-globulin) were rather rare (0.6%, 4%, and 3% of patients, respectively) and high levels were frequent (23%, 37%, and 8%, respectively).
  • The statistically significant association was not found between serum Ig concentration and lymphoma malignancy grade as well as between serum Ig concentration and immunologic origin of lymphoma.
  • T-NHL patients have more often IgA concentration level above or under normal values than B-NHL patients (p < 0.05).
  • [MeSH-major] Immunoglobulins / blood. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Blood Proteins / analysis. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Retrospective Studies. Serum Albumin / metabolism. Serum Globulins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698110.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins; 0 / Serum Albumin; 0 / Serum Globulins
  •  go-up   go-down


18. Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP: Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol; 2010 Jun 20;28(18):3035-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
  • PURPOSE: The efficacy and safety of cyclophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -tositumomab therapy were evaluated in a multicenter phase II study in patients with untreated low-grade follicular lymphoma.
  • The most common grade > or = 3 hematologic adverse events were neutropenia (87%) and thrombocytopenia (37%).
  • CONCLUSION: These mature data demonstrate that sequential therapy with a non-anthracycline-containing regimen comprising CVP followed by one cycle of tositumomab and (131)I-tositumomab produced high response rates with adequate safety and durable remissions and that this regimen represents a highly active treatment for first-line therapy of follicular non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Feasibility Studies. Follow-Up Studies. Humans. Maximum Tolerated Dose. Middle Aged. Prednisone / administration & dosage. Remission Induction. Survival Rate. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458031.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / iodine-131 anti-B1 antibody; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


19. Hughes M, Morrison A, Jackson R: Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature. Leuk Lymphoma; 2005 Jun;46(6):873-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature.
  • Primary bladder non-Hodgkin's lymphoma (NHL) is rare.
  • Using the Scotland and Newcastle lymphoma group database, 12 patients with primary bladder lymphoma were identified between 1980 and 2001, the largest single group of patients available to date.
  • Six cases were low-grade extranodal marginal zone lymphoma, 4 diffuse large B-cell lymphoma, one an ALK 1 positive anaplastic large cell lymphoma (ALKoma) and one a low-grade lymphoma unspecified.
  • Two patients (low-grade NHL) were treated with oral antibiotics (n=1) or diathermy (n=1) alone with complete resolution of disease.
  • One patient with high-grade NHL gained complete remission without conventional therapy.
  • A review of 88 additional cases in the literature support the findings that primary bladder lymphoma is associated with a good prognosis.
  • Patients with low-grade extranodal marginal zone lymphoma may respond well to simple therapies.
  • Patients with diffuse large B-cell lymphoma respond well to first-line chemotherapy regimens.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Medical Oncology / methods. Prognosis. Registries. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019532.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Etemad-Moghadam S, Tirgary F, Keshavarz S, Alaeddini M: Head and neck non-Hodgkin's lymphoma: a 20-year demographic study of 381 cases. Int J Oral Maxillofac Surg; 2010 Sep;39(9):869-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck non-Hodgkin's lymphoma: a 20-year demographic study of 381 cases.
  • Malignant lymphoma is a lymphoreticular malignancy with considerable geographic variation.
  • The objective of the present study was to provide a preliminary report on patients with head and neck non-Hodgkin's lymphoma (NHL) in a selected Iranian population.
  • In a retrospective review from 1981 through 2001, all cases of NHL occurring in the head and neck region were selected.
  • Information on 381 cases of NHL was retrieved from the archived medical records; 281 cases were nodal and 100 extranodal.
  • According to histopathologic evaluation, 72% of the specimens were intermediate-, 14% were high-, and 12% were low-grade malignancies.
  • Considering the relative frequency of head and neck lymphoma, establishment of a uniform reporting method seems necessary in order to compare different reports from various populations.
  • [MeSH-major] Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Oropharynx / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Female. Humans. Iran / epidemiology. Lymph Nodes / pathology. Male. Middle Aged. Retrospective Studies. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20538427.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


21. Schoof N, von Bonin F, Zeynalova S, Ziepert M, Jung W, Loeffler M, Pfreundschuh M, Trümper L, Kube D: Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Ann Oncol; 2009 Sep;20(9):1548-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial.
  • BACKGROUND: Recently published data indicate that host germline variations in immune genes can influence the outcome of lymphoma patients.
  • Therefore, we investigated whether polymorphisms of IL4, IL13 and IL4R genes could predict the outcome of diffuse large B-cell lymphoma (DLBCL) patients.
  • METHODS: In 228 DLBCL samples of the German High-Grade Non-Hodgkin's Lymphoma Study Group, the polymorphisms of IL4 (-524CT, rs2243250), IL13 (-1069CT, rs1800925) and IL4R (I75V, rs1805010; S503P, rs1805015; Q576R, rs1801275) were analyzed and the soluble interleukin-4 receptor (sIL4R) serum level was measured before the start of chemotherapy.
  • DLBCL patients homozygous for the IL4R I75 and low sIL4R serum levels have the most favorable OS and EFS.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • GoeScholar-Universitat Gottingen. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19515749.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-13; 0 / Receptors, Interleukin-4; 207137-56-2 / Interleukin-4
  •  go-up   go-down


22. Cikota BM, Tukić LJ, Tarabar OT, Magić ZM: Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma. J Exp Clin Cancer Res; 2007 Dec;26(4):535-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma.
  • The study included 40 B-NHL patients--13/40 patients with high- (HG) and 27/40 with low-grade (LG) lymphoma.
  • The incidence of relapse was significantly higher in MRD+ vs. MRD- B-NHL patients (Fisher's exact test, p = 0.0083).
  • Our results demonstrated positive correlation between MRD-positivity and incidence of relapse in B-NHL patients, but could not indicate significance of P53 and RAS mutations for evaluation of residual clone malignancy.
  • [MeSH-major] Genes, p53. Genes, ras. Lymphoma, B-Cell / genetics. Mutation. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365550.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Lin SY, Hsieh MS, Chen LS, Chiu YH, Yen AM, Chen TH: Diabetes mellitus associated with the occurrence and prognosis of non-Hodgkin's lymphoma. Eur J Cancer Prev; 2007 Oct;16(5):471-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabetes mellitus associated with the occurrence and prognosis of non-Hodgkin's lymphoma.
  • The aim of this case-control study was to assess the effect of preexisting diabetes mellitus on the risk of developing non-Hodgkin's lymphoma, and also to investigate whether preexisting diabetes mellitus could further affect survival after diagnosis of non-Hodgkin's lymphoma.
  • The retrospective cohort consisted of 242 study participants with pathologically confirmed non-Hodgkin's lymphoma who were referred to the Department of Radiation Oncology in Chang-Gung Memorial Hospital between January 2000 and March 2004.
  • A logistic regression model was employed to calculate the odds ratios of the risk factors we examined and then to evaluate the association between preexisting diabetes mellitus and the occurrence of non-Hodgkin's lymphoma.
  • The results showed that preexisting diabetes mellitus was an independent risk factor for the occurrence of non-Hodgkin's lymphoma (odds ratio, 1.88; 95% confidence interval, 1.22-2.89; P=0.0045).
  • When subgroup analyses regarding certain tumor or disease characteristics were performed, the impact of preexisting diabetes mellitus was found to be particularly evident in some subgroups such as the tumors of T-cell origin (P=0.0266), those with extranodal involvement (P=0.0346), and those that were not localized or low grade (P=0.0096).
  • The effect of preexisting diabetes mellitus on the risk of death from non-Hodgkin's lymphoma varied with follow-up time.
  • In the current study, preexisting diabetes mellitus was an independent risk factor for the occurrence of non-Hodgkin's lymphoma, and it was also an accelerated factor for the risk of death from causes related to non-Hodgkin's lymphoma.
  • [MeSH-major] Diabetes Complications / etiology. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923820.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Al-Maghrabi JA, Sawan AS, Kanaan HD: Hodgkin's lymphoma with exuberant granulomatous reaction. Saudi Med J; 2006 Dec;27(12):1905-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma with exuberant granulomatous reaction.
  • We report a 36-year-old woman, presented with cervical lymphadenopathy and low-grade fever.
  • She presented to our institution one year after the initial diagnosis, and a new biopsy from the cervical lymph node revealed effacement of the whole node by marked non-necrotizing granulomatous reaction.
  • These findings confirmed the diagnosis of Hodgkin's lymphoma with remarkable granulomatous reaction that almost masked the malignant component.
  • [MeSH-minor] Adult. Female. Humans. Neck

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143374.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


25. Karchenko VP, Voznyĭ EK, Belonogov AV, Bozhenko VK, Olfer'ev MA, Galil-Ogly GA: [Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma]. Vopr Onkol; 2005;51(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma].
  • The data on monoclonal antibody monotherapy (mabtera, rituximab) in 44 patients with B-cell low grade non-Hodgkin's lymphoma were assessed.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Dose-Response Relationship, Immunologic. Humans. Middle Aged. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909809.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


26. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol; 2005 Feb 20;23(6):1096-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 22 patients with low-grade non-Hodgkin's lymphoma (LGNHL), the ORR was 63% with 36% CR and median progression-free survival (PFS) has not been reached.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / metabolism. Antineoplastic Agents / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Retreatment. Rituximab. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 20;23(6):1056-8 [15657408.001]
  • (PMID = 15657402.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


27. Mohapatra PR, Bhuniya S, Garg S, Dimri K, Janmeja AK: Endobronchial non-Hodgkin's lymphoma presenting as mass lesion. Indian J Chest Dis Allied Sci; 2009 Apr-Jun;51(2):107-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial non-Hodgkin's lymphoma presenting as mass lesion.
  • Endobronchial biopsy from the mass lesion yielded low grade B-cell non-Hodgkin's lymphoma.
  • This is one of the rarest presentation of non-Hodgkin's lymphoma.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Bronchoscopy. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445447.001).
  • [ISSN] 0377-9343
  • [Journal-full-title] The Indian journal of chest diseases & allied sciences
  • [ISO-abbreviation] Indian J Chest Dis Allied Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


28. Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C: [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Orv Hetil; 2009 Oct 18;150(42):1937-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous system lymphoma is defined as an extranodal lymphoma arising in the central nervous system in the absence of systemic disease.
  • PATIENTS AND METHODS: During this period (mean follow-up of 13.2 months) from 427 patients with newly diagnosed non-Hodgkin's lymphomas, 22 primary central nervous system lymphoma was diagnosed (5.15%, 16 cerebral and 6 spinal cord lymphoma cases).
  • All central nervous system lymphoma specimens taken with neurosurgical resection or stereotaxic biopsies were confirmed histopathologically.
  • All cerebral lymphoma cases proved to be diffuse large B-cell of origin, while in epidural lymphomas low grade subtypes also occurred.
  • In cerebral lymphoma (every patients had supratentorial localization) the following combined therapy protocol was used: up to three courses of high dose methotrexate (HD MTX 3g/m 2 in a single dose for 4 hours lasting drop-infusion) were given at 4-week intervals, followed by leucovorin-rescue 24 hours after MTX infusion.
  • RESULTS: Complete remission has been achieved in 9 patients with cerebral and in 4 patients with spinal cord lymphoma (13/22; 59.0%), however, one relapsed patient became resistant and later expired, despite salvage therapy.
  • Mean of the overall survival (OS) in cerebral lymphoma was 19.5 (3-46, median of 10) months, in epidural group 14.1 (2-76, median of 5) months, whilst mean time to progression (TTP) was 4.5 (2-6.5, median of 4 months).
  • CONCLUSION: In primary central nervous system lymphoma, basic treatment HD methotrexate together with intrathecal combination of methotrexate + cytosin-arabinosid + dexamethasone followed by whole-brain irradiation of at least 30 Gy could produce a medium response rate in our study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Epidural Space. Female. Humans. Hungary / epidemiology. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Positron-Emission Tomography. Prednisone / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Salvage Therapy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812012.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


29. Paydas S, Ergin M, Erdogan S, Seydaoglu G: Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma; 2007 Feb;48(2):389-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in non-Hodgkin's lymphomas.
  • Cox-2 has been studied in solid tumors; however, studies about the role of Cox-2 in non-Hodgkin's lymphomas (NHL) are limited.
  • To this end, Cox-2 expression was determined in 177 cases with NHL.
  • In histological terms, 60 cases (33%) had low grade and 117 (67%) had aggressive lymphoma.
  • In conclusion Cox-2 expression is seen about 60% of the cases with NHL and is associated with aggressive morphology.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Mantle-Cell / enzymology. Lymphoma, Non-Hodgkin / enzymology. Lymphoma, T-Cell, Peripheral / enzymology. Membrane Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325901.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


30. Bhurgri Y, Pervez S, Bhurgri A, Faridi N, Usman A, Kazi LA, Ahmed R, Kayani N, Hasan SH: Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002. Asian Pac J Cancer Prev; 2005 Jul-Sep;6(3):364-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002.
  • This first population-based study of non- Hodgkin lymphoma (NHL) from any region in Pakistan, provides an overview of the incidence pattern and time trends in Karachi and generates hypotheses for future experimental research.
  • Epidemiological data for 429 incident (1(st) Jan 1995 to 31(st) Dec 2002), microscopically verified nodal and extra-nodal NHL cases, registered at the Karachi Cancer Registry (KCR) for Karachi South, were reviewed.
  • A gradual increase in the annual incidence was observed during the study period, with NHL incidence rate increasing in 2002 to 8.4/100,000 in men and 6.5/100,000 in women, almost double the 1995 rates.
  • NHL affected all age groups in both genders and for each group the ASIR was higher among men than women, with an overall gender ratio of 1.9.
  • The adult to childhood ratios were 8.6 (M) and 10.7 (F).
  • B-cell NHL comprised 81.0% of NHL in males and 87.3% in females.
  • One fourth of the NHL cases were extra-nodal, the largest group was of gastrointestinal origin (54.1% M, 38.5% F).
  • Children and adolescents were at the highest risk of developing NHL, especially the 5-9 year olds, in both genders.
  • The incidence rates of NHL registered in Karachi South are likely to be a reflection of non-AIDS-associated NHL.
  • Estimated HIV/AIDS incidence was too low during the study period in this population to have an impact on NHL incidence.
  • The preponderance of low and intermediate grade lymphomas, paucity of central nervous system NHL and a higher childhood NHL component support this hypothesis.
  • NHL correlation with HIV/AIDS status and studies identifying risk factors of non- HIV/AIDS associated NHL (childhood viral infections, Hepatitis C virus, and Helicobacter pylori) are potential areas for future experimental and epidemiological research.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Epidemiologic Studies. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Pakistan / epidemiology. Sex Factors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236001.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


81. Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA, Cancer and Leukemia Group B: Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol; 2009 Apr;63(5):793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the efficacy and toxicity of the topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), in patients with relapsed lymphoma and to correlate 9-AC plasma concentrations with response and toxicity.
  • METHODS: Eligible patients had relapsed Hodgkin lymphoma (HL) treated with one or two prior regimens, low grade non-Hodgkin's lymphoma (NHL) treated with one or two prior regimens, or aggressive NHL treated with one prior regimen.
  • RESULTS: CALGB 9551 accrued 37 patients from April 1996 through October 2000; one patient with HD, 18 patients with indolent lymphoma, and 17 patients with aggressive lymphoma.
  • Significant grade 3 and 4 toxicities included neutropenia (66%), anemia (31%), and thrombocytopenia (36%), with 20% of patients experiencing grade 3 or 4 infection.
  • CONCLUSION: Single agent 9-AC has modest activity in aggressive non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Camptothecin / analogs & derivatives. Hodgkin Disease / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Prognosis. Salvage Therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648813.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5MB77ICE2Q / 9-aminocamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


82. Basu D, Yaranal PJ, Kalyan K, Soundararaghavan J: Mantle cell lymphoma--a clinicopathological study of 13 cases. Malays J Pathol; 2005 Jun;27(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma--a clinicopathological study of 13 cases.
  • Mantle cell lymphoma is an uncommon non-Hodgkin's lymphoma.
  • In a period of four years, 13 cases of mantle cell lymphoma were diagnosed in our department, comprising 3.1% of all non-Hodgkin's lymphoma diagnosed.
  • Despite certain morphological similarity to other low-grade lymphomas, mantle cell lymphoma has a characteristic appearance of its own.
  • It is more aggressive than other low-grade lymphomas and hence needs to be accurately diagnosed.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / immunology. Biopsy, Needle. Bone Marrow Examination. Cyclin D1 / immunology. Female. Humans. Immunohistochemistry. Immunophenotyping. Lymph Node Excision / statistics & numerical data. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676688.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antigens, CD20; 136601-57-5 / Cyclin D1
  •  go-up   go-down


83. Morris E, Mackinnon S: Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci; 2005 Feb;32(1):73-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
  • We report the outcome following RIT for NHL in 88 patients (LG-NHL n = 41, HG-NHL n = 37, MCL n = 10).
  • Grade III-IV acute GVHD developed in 4 patients and chronic GVHD in 6 patients.
  • With a median follow-up of 36 months (range 18-60), the actuarial overall survival (OS) at 3 years was 34% for HG-NHL, 60% for MCL and 73% for LG-NHL (p < or = 0.001).
  • The 100-day and 3-year TRM for patients with LG-NHL were 2% and 11%, respectively, and were better (p = 0.01) than for patients with HG-NHL (27% and 38%, respectively).
  • The actuarial current progression free survival (PFS) at 3 years, including those who achieved remission following DLI for progression, was 65% for LG-NHL 50% for MCL and 34% for HG-NHL (p = 0.002).
  • Patients with relapsed LG-NHL and CLL achieve excellent PFS with extremely low TRM and GVHD, even when matched family donors are unavailable.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Recurrence. Time Factors. Transplantation Chimera. Transplantation Conditioning. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737876.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


84. Cornejo-Juárez P, Volkow-Fernández P, Avilés-Salas A, Calderón-Flores E: AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico. Rev Invest Clin; 2008 Sep-Oct;60(5):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
  • BACKGROUND: Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS.
  • With the advent of highly active antiretroviral therapy (HAART), the incidence and mortality of AIDS-related opportunistic infections and Kaposi's sarcoma has fallen dramatically, this trend is not observed so clearly for NHL.
  • Our objective was to review the clinical spectrum of patients with AIDS-associated NHL and to analyze the impact of HAART on survival at an oncological tertiary center.
  • MATERIAL AND METHODS: We reviewed all medical records and histopathologic tissue of patients with HIV-associated NHL seen from January 1990 to September 2007 at the Instituto Nacional de Cancerologia in Mexico City.
  • RESULTS: Eighty seven HIV-positive patients were diagnosed with NHL (diffuse large B-cell lymphoma n=69; Burkitt-like n=8; pleomorphic large cell n=7; low-grade n=2, and angiocentric n=1).
  • Overall, 38 patients (43.7%) achieved complete response to NHL therapy, including only 14.3% patients in the non-HAART compared with 57.6% in the HAART group (p < or = 0.0001).
  • Two patients (7.1%) in the non-HAART were alive compared with 37 (63.8%) in the HAART group (p < or = 0.0001).
  • CONCLUSIONS: Patients with NHL-HIV who were able to receive treatment with HAART and were sufficiently healthy to receive optimal chemotherapy treatment showed a significantly better prognosis.
  • [MeSH-major] Cancer Care Facilities / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Mexico / epidemiology. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227434.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


85. Sattar T, Griffeth LK, Latifi HR, Glass J, Munker R, Lilien DL: PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas. J La State Med Soc; 2006 Jul-Aug;158(4):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas.
  • Malignant non-Hodgkin lymphomas (NHLs) are commonly staged according to the Ann Arbor staging system developed for Hodgkin's lymphoma.
  • In the present study, we investigated 77 untreated patients with different histologies of NHL both with conventional imaging techniques and FDG-PET.
  • PET imaging resulted, both in high/intermediate grade and indolent NHLs, in a higher stage in more than 20% of cases.
  • In the subtype of high grade NHL diffuse large B cell lymphoma, upstaging by PET appears to be clinically relevant as a marker for a more aggressive tumor.
  • In low grade NHL, stage changes were less pronounced.
  • However, even in low-grade NHL, clear indications exist for performing PET imaging.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Medical Audit. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022364.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


86. Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL: Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol; 2005 Nov 1;23(31):7985-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
  • PURPOSE: To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab.
  • The single therapeutic dose following a dosimetric dose was adjusted to give the same total body dose (in Gy) as that used for the original dose, or was attenuated if the platelet count was less than 150,000 per mm(3) or if the prior treatment resulted in grade 4 cytopenias lasting longer than 7 days.
  • Grade 3/4 neutropenia and thrombocytopenia occurred in 50% and 43% of patients, respectively, similar to initial treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / immunology. Female. Humans. Immunoconjugates / therapeutic use. Iodine Radioisotopes / therapeutic use. Lymphoma, Follicular / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Retreatment. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Jan 1;24(1):212
  • (PMID = 16204016.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Immunoconjugates; 0 / Iodine Radioisotopes; 0 / iodine-131 anti-B1 antibody
  •  go-up   go-down


87. Lahiani Ben Salah H, Daoud J: [Primary cervical epidural low-grade non-hodgkin's lymphoma: a case report and review of the literature]. Cancer Radiother; 2008 Dec;12(8):863-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cervical epidural low-grade non-hodgkin's lymphoma: a case report and review of the literature].
  • [Transliterated title] Le lymphome non-hodgkinien de bas grade épidural cervical primitif: à propos d'un cas et revue de la littérature.
  • Primary epidural cervical non-hodgkin's low-grade lymphomas is exceptional.
  • The histological study revealed a small cells lymphoma.
  • We review literature to describe epidemiological, clinical and therapeutic features with evolutive aspects in primary epidural non-hodgkin's lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage


88. Laane E, Tani E, Björklund E, Elmberger G, Everaus H, Skoog L, Porwit-MacDonald A: Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma. Cytometry B Clin Cytom; 2005 Mar;64(1):34-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma.
  • BACKGROUND: Fine-needle aspiration (FNA) with immunophenotyping by immunocytochemistry (IC) on cytospins has recently received increased consideration in the diagnosis of lymphoma.
  • The aim of our study was to establish the diagnostic value of a four-color flow cytometric (FCM) panel, including cytoplasmic Bcl-2, in cytologic diagnosis of malignant non-Hodgkin's lymphoma (NHL) and reactive lymphoid hyperplasia (RH).
  • FCM gave correct immunologic diagnosis in 95% of low-grade B-cell NHLs, 78% of high-grade B-cell NHLs, and 53% of T-cell lymphomas.
  • CONCLUSION: Our FCM panel allowed precise classification of NHL in FNA material in 89.5% of all samples.
  • Bcl-2 staining can be recommended for primary differentiation between reactive hyperplasia and NHL.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Lymphoma, Non-Hodgkin / diagnosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pseudolymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. B-Lymphocytes / chemistry. B-Lymphocytes / pathology. Biopsy, Fine-Needle. CD4-CD8 Ratio. Cell Proliferation. Child. Child, Preschool. Female. Humans. Immunoglobulin kappa-Chains / analysis. Immunoglobulin lambda-Chains / analysis. Lymphocyte Count. Lymphoma, T-Cell / blood. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Sensitivity and Specificity. T-Lymphocytes / chemistry. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15669024.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


89. Radan L, Fischer D, Bar-Shalom R, Dann EJ, Epelbaum R, Haim N, Gaitini D, Israel O: FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging; 2008 Aug;35(8):1424-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG avidity and PET/CT patterns in primary gastric lymphoma.
  • PURPOSE: The use of 18F-fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in primary gastric lymphoma (PGL) is challenging due to physiologic FDG activity in the stomach and variability in the degree of uptake in various histologic subtypes.
  • METHODS: Sixty-two PET/CT studies of newly diagnosed PGL were reviewed (24 low-grade mucosa-associated lymphoid tissue [MALT], 38 aggressive non-Hodgkin's lymphoma [AGNHL]).
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Lymphoma / diagnosis. Lymphoma / metabolism. Positron-Emission Tomography / methods. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Tissue Distribution


90. Yamamoto S, Nakase H, Yamashita K, Matsuura M, Takada M, Kawanami C, Chiba T: Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol; 2010 Apr;45(4):370-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal follicular lymphoma: review of the literature.
  • Gastrointestinal follicular lymphoma (GI-FL) is a relatively rare disease, accounting for only 1%-3.6% of gastrointestinal non-Hodgkin's lymphoma.
  • FL is a low-grade lymphoma that usually develops very slowly.
  • If the lymphoma causes no symptoms, immediate treatment may not be necessary.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / therapy. Lymphoma, Follicular / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Kyoto University Research Information Repository - Articles. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 May;128(6):1579-605 [15887153.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):113-9 [16648662.001]
  • [Cites] Blood. 2000 Feb 1;95(3):783-9 [10648386.001]
  • [Cites] Ann Oncol. 2006 May;17 (5):780-4 [16497824.001]
  • [Cites] Leukemia. 1993 Feb;7(2):268-73 [8426481.001]
  • [Cites] Dig Dis Sci. 2001 Mar;46(3):567-70 [11318534.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1031-5 [17353993.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1355-61 [18684042.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):432-9 [11295923.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E86-7 [17440873.001]
  • [Cites] Histopathology. 1984 Jul;8(4):641-56 [6479906.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Intern Med. 2007;46(3):141-2 [17268132.001]
  • [Cites] Recent Results Cancer Res. 2000;156:116-24 [10802871.001]
  • [Cites] J Mol Diagn. 2007 Sep;9(4):530-7 [17652637.001]
  • [Cites] N Engl J Med. 1987 Jan 8;316(2):79-84 [3537802.001]
  • [Cites] Hepatogastroenterology. 2007 Sep;54(78):1658-61 [18019688.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):105-13 [12507894.001]
  • [Cites] J Clin Pathol. 2008 Mar;61(3):377-81 [17601964.001]
  • [Cites] J Clin Gastroenterol. 2008 Oct;42(9):997-1002 [18719510.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):763-5 [18207144.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1563-9 [10995001.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):408-10 [12902896.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Can J Gastroenterol. 1997 Jan-Feb;11(1):31-4 [9113795.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):735-44 [11298531.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jan;21(1):17-29 [9443038.001]
  • [Cites] Mod Pathol. 2000 May;13(5):586-90 [10824932.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8018-24 [16204012.001]
  • [Cites] Endoscopy. 2009 Feb;41(2):175-8 [19214900.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):442-52 [8604811.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):772-84 [15352980.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1327-35 [1376556.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Aug;5(8):e30 [17625984.001]
  • [Cites] Histopathology. 1998 Feb;32(2):116-25 [9543667.001]
  • [Cites] Ann Hematol. 2004 May;83(5):276-8 [15060746.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):484-8 [9130997.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Feb;33(2):213-6 [11793448.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):343-6 [18067068.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Ann Hematol. 2002 Apr;81(4):228-31 [11976827.001]
  • [Cites] Gut. 2003 Jun;52 Suppl 4:iv48-50 [12746269.001]
  • [Cites] Haematologica. 1992 Mar-Apr;77(2):156-61 [1398301.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1083-100 [15488559.001]
  • [Cites] Gastrointest Endosc. 2001 Jul;54(1):92-6 [11427853.001]
  • [Cites] Springer Semin Immunopathol. 1990;12(2-3):239-50 [2205943.001]
  • [Cites] Mod Pathol. 2009 Jul;22(7):940-9 [19396151.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Nov;5(11):A24 [17981239.001]
  • [Cites] Intern Med. 2007;46(11):705-9 [17541220.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):652-9 [17582800.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):175-83 [16721817.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] Acta Oncol. 2001;40(2-3):213-23 [11441933.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] J Clin Gastroenterol. 2002 Feb;34(2):155-9 [11782611.001]
  • [Cites] Clin Transl Oncol. 2007 Jul;9(7):471-2 [17652063.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E26-7 [17285496.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2456-64 [9310498.001]
  • [Cites] Arch Pathol Lab Med. 2004 Sep;128(9):1035-8 [15335250.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):218-24 [8426197.001]
  • [Cites] Hum Pathol. 1999 May;30(5):581-7 [10333231.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Hematol Oncol. 1983 Apr-Jun;1(2):187-92 [6376315.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):793-800 [11843811.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5 [9308704.001]
  • [Cites] Gastrointest Endosc. 2009 Jan;69(1):158-9; discussion 159 [19111697.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):875-83 [11420458.001]
  • [Cites] Endoscopy. 2010 Jan;42(1):86; author reply 87 [20066597.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1556; author reply 1556-7 [14628813.001]
  • [Cites] J Mol Diagn. 2003 Aug;5(3):168-75 [12876207.001]
  • [Cites] Blood. 1986 Oct;68(4):837-45 [3530348.001]
  • [Cites] Blood. 2002 May 15;99(10):3806-12 [11986240.001]
  • [Cites] J Exp Med. 1986 Jul 1;164(1):315-20 [3014037.001]
  • [Cites] Intern Med. 2006;45(5):309-11 [16596000.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1641-9 [11117785.001]
  • [Cites] Pathol Res Pract. 2007;203(9):691-4 [17643847.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):547-52 [18687756.001]
  • [Cites] Cell. 1986 Oct 10;47(1):19-28 [2875799.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Surg Pathol. 1983 Jun;7(4):363-72 [6869665.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Gastroenterol. 2002 Sep;35(3):285-6 [12192212.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E39 [17285511.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1046-51 [9831200.001]
  • [Cites] Science. 1968 Dec 20;162(3860):1396-7 [4177362.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] World J Gastroenterol. 2004 Sep 1;10(17):2602-4 [15300917.001]
  • [Cites] J Gastroenterol. 2003;38(6):584-7 [12856675.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):365-72 [17134735.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):743-8 [11251169.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Cell. 1985 Jul;41(3):899-906 [3924412.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Intern Med. 2008;47(13):1277-8 [18591856.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1852-6 [12200703.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] J Gastroenterol. 2003;38(5):512-3 [12768397.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E8-9 [18278712.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2499-505 [10561315.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • (PMID = 20084529.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 126
  •  go-up   go-down


91. Corns R, Crocker M, Kumar A, Salisbury J, Tolias C, Sadler G, Hill M: Low grade cerebellar T-cell lymphoma: a novel response to treatment; a case report. Acta Neurochir (Wien); 2010 Jun;152(6):1075-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade cerebellar T-cell lymphoma: a novel response to treatment; a case report.
  • Low-grade primary T-cell lymphoma of the central nervous system is extremely rare.
  • Biopsy of this lesion revealed features of non-Hodgkin's lymphoma with histochemical analysis confirming T-cell phenotype and a Ki67 proliferation index of only 1%.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Biomarkers, Tumor / analysis. Biopsy. Cerebellum / pathology. Combined Modality Therapy. Dexamethasone / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Neurologic Examination. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936608.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 7S5I7G3JQL / Dexamethasone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Lohan DG, Alhajeri AN, Cronin CG, Roche CJ, Murphy JM: MR enterography of small-bowel lymphoma: potential for suggestion of histologic subtype and the presence of underlying celiac disease. AJR Am J Roentgenol; 2008 Feb;190(2):287-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR enterography of small-bowel lymphoma: potential for suggestion of histologic subtype and the presence of underlying celiac disease.
  • OBJECTIVE: The objective of our study was to evaluate the morphologic appearances of small-bowel lymphoma using MR enterography to identify key morphologic traits capable of providing an association between imaging manifestations and likely histologic diagnosis.
  • MATERIALS AND METHODS: Over a 54-month period, 10 patients with subsequently confirmed small-bowel lymphoma were imaged using a standardized MR enterography technique.
  • This patient group comprised 10 patients with non-Hodgkin's lymphoma (NHL) of various subtypes.
  • No cases of Hodgkin's lymphoma were encountered.
  • Analysis revealed celiac NHL enteropathy to have a tendency toward localization to a single, long (> 10 cm), smooth continuous bowel segment, often with aneurysmal loop dilatation, in the absence of a distinct mesenteric or antimesenteric distribution.
  • Luminal stricturing was encountered in cases of low-grade lymphoma, whereas mesenteric fat infiltration represented a characteristic of high-grade disease.
  • CONCLUSION: We describe the characteristics of small-bowel lymphoma on MR enterography, identifying a number of key features that may help the interpreting radiologist in suggesting the underlying histologic subtype and whether the presence of underlying celiac disease is likely.
  • [MeSH-major] Celiac Disease / diagnosis. Celiac Disease / etiology. Intestinal Neoplasms / complications. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Lymphoma / complications. Lymphoma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Reproducibility of Results. Sensitivity and Specificity


93. Jezersek Novaković B, Vovk M, Juznic Setina T: A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003. Ann Hematol; 2006 Dec;85(12):849-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary gastric lymphomas are the most common extranodal non-Hodgkin's lymphomas and are divided into indolent (low grade) and aggressive (high grade) types.
  • To determine the role of surgery as the initial treatment modality, we performed this retrospective single-center research on 245 patients with primary gastric lymphoma who were treated according to our protocol between 1990 and 2003.
  • According to the histology, 59.2% had diffuse large B-cell lymphoma (DLCL), 26.1% MALT lymphoma, 9.8% mixed lymphoma (indolent and aggressive at the same time), while other types were infrequent.
  • In total, 161 patients (65.7%) were treated with surgical resection as the initial treatment, which was then followed or not by additional therapy (chemotherapy, chemotherapy and radiotherapy, radiotherapy) depending on the histological type of lymphoma and the extent of residual disease after surgery.
  • The selection of treatment (chemotherapy, chemotherapy and radiotherapy, radiotherapy or Helicobacter pylori eradication only) was based on the histological type of lymphoma, considering also the patients' physical condition.
  • In the MALT lymphoma and mixed lymphoma types, there were no differences in the disease-specific survival between both treatment groups.
  • [MeSH-major] Lymphoma / mortality. Lymphoma / surgery. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Helicobacter Infections / epidemiology. Helicobacter pylori / pathogenicity. Humans. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944146.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Kolokotronis A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, Antoniades D: Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar;99(3):303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study.
  • OBJECTIVE: Non-Hodgkin's lymphomas (NHL) are the third most common group of malignant lesions in the oral cavity and maxillofacial region.
  • The purpose of the present study is to analyze the clinical signs and symptoms and the clinical staging of B-cell NHL of this region.
  • STUDY DESIGN: Eighteen adults, with B-cell NHL manifestations of the oral cavity and maxillofacial region, were available for this study.
  • Tonsillar NHL was the most frequent site occurring in 8 patients followed by NHL of the oral cavity, of the salivary glands, and of the mandible.
  • Grading revealed that most cases were high grade (11 cases), followed by the cases of low grade (5 cases) and intermediate grade (2 cases).
  • CONCLUSIONS: The B-cell NHL may involve both osseous and soft tissues of the oral cavity and maxillofacial region.
  • Most patients have high grade disease.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716836.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar MV, Podoloff DA, Macapinlac HA: Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol; 2005 Dec 14;11(46):7284-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To demonstrate the (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) findings in patients with non-Hodgkinos lymphoma (NHL) involving the gastrointestinal (GI) tract and the clinical utility of modality despite of the known normal uptake of FDG in the GI tract.
  • METHODS: Thirty-three patients with biopsy-proven gastrointestinal NHL who had undergone FDG-PET scan were included.
  • RESULTS: Twenty-five patients had a high-grade lymphoma and eight had a low-grade lymphoma.
  • In high-grade lymphoma, PET showed focal nodular or diffuse hypermetabolic activity.
  • After the therapy, the patients whose biopsies showed no evidence of lymphoma had a lower uptake without focal lesions.
  • In patients whose post-treatment biopsies showed lymphoma, the SUV(max)+/-SD was 9.42+/-6.27.
  • Low-grade follicular lymphomas of the colon and stomach showed diffuse hypermetabolic activity in the bowel wall (SUV(max) 8.2 and 10.3, respectively).
  • The SUV(max) was 2.02-3.8 (mean 3.02) in the stomach lesions of patients with MALT lymphoma.
  • ONCLUSION: (18)F-FDG PET contributes to the diagnosis of high-grade gastrointestinal non-Hodgkin's lymphoma, even when there is the normal background FDG activity.
  • Low-grade NHL demonstrates FDG uptake but at a lesser intensity than seen in high-grade NHL.
  • [MeSH-major] Gastrointestinal Neoplasms / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437629.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC4725130
  •  go-up   go-down


96. Todisco M: Relapse of high-grade non-Hodgkin's lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH. Am J Ther; 2006 Nov-Dec;13(6):556-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of high-grade non-Hodgkin's lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH.
  • Patients with relapse of high-grade non-Hodgkin lymphoma (NHL) after autologous stem cell transplantation (auto-SCT) generally have a poor prognosis.
  • With a combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH, we already reported 100% global response in 8 patients with relapse of low-grade NHL after single or combined chemotherapy and a therapy-free period of > or = 6 months.
  • This provided the rationale to evaluate the same pharmacological association in a patient with relapse of high-grade NHL after auto-SCT performed 2 years before.
  • Our result and severe toxicities associated with conventional salvage treatments suggest in a relapse of high-grade NHL after auto-SCT, further clinical trials using the pharmacological association we employed in this case.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Adrenocorticotropic Hormone / administration & dosage. Adult. Bromocriptine / administration & dosage. Cyclophosphamide / administration & dosage. Humans. Male. Melatonin / administration & dosage. Recurrence. Retinoids / administration & dosage. Somatostatin / administration & dosage. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MELATONIN .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122540.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoids; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 8N3DW7272P / Cyclophosphamide; 9002-60-2 / Adrenocorticotropic Hormone; JL5DK93RCL / Melatonin
  •  go-up   go-down


97. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L: Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol; 2005 May;52(5):847-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary cutaneous B-cell lymphoma with rituximab.
  • Intravenous administration of rituximab has been used for the treatment of patients with low-, intermediate-, and high-grade B-cell non-Hodgkin's lymphomas and is a registered treatment modality for this indication.
  • Treatment of primary cutaneous B-cell lymphoma (CBCL) with intralesionally or systemically administered rituximab has been described only in a few cases.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / analysis. Female. Humans. Injections, Intralesional. Injections, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Rituximab

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858476.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


98. Burns DS, Azzouz F, Sledge R, Rutledge C, Hincher K, Monahan PO, Cripe LD: Music imagery for adults with acute leukemia in protective environments: a feasibility study. Support Care Cancer; 2008 May;16(5):507-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to determine the feasibility and possible benefits of a music imagery intervention for patients hospitalized in a protective environment for the treatment of acute leukemia or high-grade non-Hodgkin's lymphoma.
  • However, a subgroup of individuals with low baseline negative affect who received the intervention reported significantly less anxiety at discharge than individuals with low baseline negative affect who did not receive the intervention.
  • [MeSH-major] Anxiety / psychology. Imagery (Psychotherapy). Leukemia / psychology. Lymphoma, Non-Hodgkin / psychology. Music Therapy
  • [MeSH-minor] Acute Disease. Adult. Affect. Aged. Fatigue. Feasibility Studies. Female. Hematologic Neoplasms. Humans. Male. Middle Aged. Relaxation Therapy. Severity of Illness Index. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Music Ther. 2001 Spring;38(1):51-65 [11407965.001]
  • [Cites] Psychooncology. 2005 Aug;14(8):607-17 [15651053.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2723-9 [14669295.001]
  • [Cites] J Music Ther. 2001 Fall;38(3):193-211 [11570932.001]
  • [Cites] J Psychosom Res. 2003 Apr;54(4):289-92 [12670604.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):43-6 [9671330.001]
  • [Cites] J Music Ther. 2005 Fall;42(3):185-99 [16086604.001]
  • [Cites] J Music Ther. 2004 Fall;41(3):192-214 [15327345.001]
  • [Cites] Health Psychol. 1995 Mar;14(2):101-8 [7789344.001]
  • [Cites] Cancer. 1997 Nov 15;80(10):1936-44 [9366296.001]
  • [Cites] Pain Manag Nurs. 2003 Sep;4(3):112-23 [14566709.001]
  • [Cites] J Adv Nurs. 1997 Jan;25(1):68-78 [9004013.001]
  • [Cites] Leukemia. 1998 Apr;12(4):586-92 [9557618.001]
  • [Cites] Psychooncology. 1999 Jan-Feb;8(1):64-73 [10202784.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(1):77-83 [15502851.001]
  • [Cites] J Adv Nurs. 1999 Aug;30(2):439-47 [10457247.001]
  • [Cites] Health Psychol. 1997 Jul;16(4):390-400 [9237092.001]
  • [Cites] Bone Marrow Transplant. 2000 Feb;25(3):315-8 [10673704.001]
  • [Cites] Semin Oncol Nurs. 1995 Nov;11(4):279-88 [8578036.001]
  • [Cites] J Pers Soc Psychol. 1988 Jun;54(6):1063-70 [3397865.001]
  • (PMID = 17891547.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / 5F32AT001144-02
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


99. Chakraborty J, Paul PC, Sarkar R, Rao RN: Primary non-Hodgkin's lymphoma of breast: a case report. Indian J Pathol Microbiol; 2007 Apr;50(2):315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of breast: a case report.
  • Primary breast lymphoma is a relatively uncommon neoplasm, majority being of B-cell origin.
  • Though cytologic diagnosis of breast lymphoma is an easy procedure and provides guidance for appropriate pre-operative management, it is often impossible to differentiate a low grade lymphoma from reactive proliferation.
  • Lymphoepithelial lesions were identified histologically, and the majority of the cell population were confirmed as lymphoma cells of B-cell origin on immunohistochemistry.
  • This case highlights the limitations of cytology and the importance of histological examination supported by immunohistochemistry for making a diagnosis of low grade primary breast lymphoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Adult. Antigens, CD20 / metabolism. Antigens, CD79 / metabolism. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883054.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / CD79A protein, human
  •  go-up   go-down


100. Wu Y, Liu WL, Sun HY, Xu HZ: [Expression of P120ctn in non-Hodgkin's lymphoma and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun;14(3):508-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of P120ctn in non-Hodgkin's lymphoma and its significance].
  • To evaluate the expression of P120ctn in non-Hodgkin's lymphoma (NHL) and to explore its clinical significance, immunohistochemistry stain method was applied to comparatively investigate the protein expression of P120ctn in paraffin-embedded lymph node tissue slices from 40 cases of NHL and 10 cases of reactive hyperplasia of lymph node.
  • The results showed that P120ctn was not detected in reactive hyperplasia of lymph node, but was detected in 55% (22/40) cases of NHL.
  • P120ctn expression increased with the tumor malignancy of NHL, there was a significant difference between the expression rates of P120ctn in low grade (16.7%, 2/12) and intermediate to high grade malignant (71.4%, 20/28) NHL (P < 0.001).
  • Moreover, P120ctn was also detected in vascular endothelial cells of NHL.
  • It is concluded that the level of P120ctn expression is closely related to the malignant grade of NHL, it suggests that P120ctn possibly plays an important role in the malignant proliferation of lymphoma with a certain significance in diagnosis and therapy of lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800931.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Phosphoproteins; 0 / delta catenin
  •  go-up   go-down






Advertisement